policies covering approximately 4.6 million lives.
-- Targeting inclusion of quantitative HER2 scores in all Oncotype DX
reports by the end of 2008.
-- Conducting a study using Oncotype DX in breast cancer patients treated
with aromatase inhibitors with the goal of reporting results this year.
-- Received first trial specimens for our clinical validation study, which
we expect to begin in the second half of 2008.
-- Received milestone payment from Bristol-Myers Squibb related to Genomic
Health's program to identify genes to predict response to cetuximab
-- Established collaborators and identified sources of clinical samples
to further our prostate and lung cancer programs.
-- Began gene identification work to develop a prognostic test for
patients with renal cell carcinoma, clear cell type, under the Pfizer
collaboration announced in January of 2008.
-- Initiated a study supporting Japanese investigators as they gain
clinical experience with Oncotype DX for early-stage breast cancer
-- Processing samples from patients in Canada, Ireland and Peru enrolled
in the National Cancer Institute-sponsored TAILORx study, which has
Conference Call Details
To access the live conference call today, August 5, at 4:30 p.m.
Eastern Time via phone, please dial (877) 356-8064 from the United States
and Canada or (706) 758-4314 internationally. The conference ID is
56195752. Please dial in approximately ten minutes prior to the start of
the call. A telephone replay will be available beginning approximately one
hour after the call through August 12 and may be accessed by dialing (
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved